Recombinant 60S ribosomal protein L23 (rpl-23)

What is the primary function of Recombinant 60S Ribosomal Protein L23 (rpl-23) in cellular processes?

Recombinant 60S ribosomal protein L23 (rpl-23) functions primarily as a negative regulator of cellular apoptosis. Research has demonstrated that when RPL23 expression is reduced, there is a measurable suppression of cellular viability, increased apoptosis, and G1-S cell cycle arrest. These findings suggest that RPL23 plays a critical role in maintaining cellular homeostasis through regulation of the cell cycle and apoptotic pathways. Additionally, RPL23 exhibits RNA-binding properties, indicating its involvement in RNA metabolism beyond its structural role in ribosomes. For researchers investigating cellular life-death balance mechanisms, RPL23 represents a valuable target for understanding how ribosomal proteins participate in non-canonical functions .

What experimental methods are recommended for detecting Recombinant 60S Ribosomal Protein L23 (rpl-23) expression?

When investigating RPL23 expression, researchers should employ multiple detection methods to ensure robust results:

• Western Blotting Protocol:

  • Extract proteins using RIPA lysis buffer

  • Separate by SDS polyacrylamide gel electrophoresis

  • Transfer to membranes and incubate with RPL23-specific antibodies (1:1000 dilution, Proteintech recommended)

  • Visualize using enhanced chemiluminescence

  • Quantify band intensity using image analysis software (e.g., Image J)

• qPCR Methodology:

  • Extract total RNA using TRIzol reagent

  • Design primers specific to RPL23 (Forward: 5'-TCCTCTGGTGCGAAATTCCG-3', Reverse: 5'-CGTCCCTTGATCCCCTTCAC-3')

  • Synthesize cDNA and perform qPCR using SYBR Green PCR Master Mix

  • Calculate relative expression using the 2^-ΔΔCt method

  • Use β-actin as internal control for normalization

For comprehensive expression analysis, it is advisable to complement these methods with immunohistochemistry when working with tissue samples to assess spatial distribution patterns within tissues .

How does Recombinant 60S Ribosomal Protein L23 (rpl-23) expression differ between normal and cancer cells?

Research demonstrates significant differences in RPL23 expression between normal and cancer cells, with consistent upregulation observed in multiple cancer types:

In hepatocellular carcinoma (HCC), RPL23 expression positively correlates with adverse clinical features, including tumor vascular invasion (p=0.0070), lung metastasis (p=0.0469), and advanced TNM stage (p=0.0346). These expression patterns suggest that RPL23 upregulation may be a common feature across different cancer types, making it a potential biomarker for disease progression and therapeutic targeting. Researchers should consider controlling for tissue type and disease stage when designing comparative expression studies involving RPL23 .

What signaling pathways does Recombinant 60S Ribosomal Protein L23 (rpl-23) interact with to regulate apoptosis?

RPL23 regulates apoptosis through a complex regulatory circuit involving the Miz-1/c-Myc axis. Current research indicates that:

• When RPL23 expression is reduced:

  • Miz-1 is upregulated

  • Transactivation of cell cycle inhibitors p15^Ink4b and p21^Cip1 occurs

  • c-Myc, the functional repressor of Miz-1, is downregulated

  • This cascade promotes cell cycle arrest and apoptosis

• When RPL23 is overexpressed (as in higher-risk MDS patients):

  • Miz-1 expression decreases

  • c-Myc expression increases

  • Miz-1-dependent induction of p15^Ink4b and p21^Cip1 is suppressed

  • This leads to apoptotic resistance

This RPL23/Miz-1/c-Myc regulatory circuit forms a feedback loop that links efficient RPL23 expression with c-Myc's function to suppress Miz-1-induced Cdk inhibitors. For researchers investigating apoptotic mechanisms, it is critical to consider this feedback loop when designing experiments targeting RPL23. Gene expression analysis should include assessment of Miz-1, c-Myc, p15^Ink4b, and p21^Cip1 to fully understand the pathway dynamics .

What methodologies are most effective for RPL23 gene silencing in experimental models?

For effective RPL23 silencing in experimental models, researchers should consider:

• siRNA Transfection Protocol:

  • Design at least 3 different siRNA sequences targeting different regions of RPL23 mRNA

  • Transfect at 50-100 nM concentration using lipid-based transfection reagents

  • Include scrambled siRNA controls

  • Validate knockdown efficiency by western blot and qPCR (recommended >70%)

  • Optimal assessment time points: 48-72 hours post-transfection

• shRNA Stable Knockdown:

  • For long-term studies, develop stable cell lines using lentiviral shRNA vectors

  • Select transduced cells with appropriate antibiotics

  • Confirm knockdown stability over multiple passages

  • Consider doxycycline-inducible systems for temporal control

• CRISPR-Cas9 Gene Editing:

  • Design guide RNAs targeting exonic regions of RPL23

  • Screen multiple clones to identify complete knockouts

  • Verify protein absence by western blot

  • Consider conditional knockout systems for essential genes like RPL23

When evaluating RPL23 knockdown effects, researchers should assess both direct molecular responses (changes in target gene expression) and phenotypic outcomes (cell proliferation, migration, invasion) to comprehensively understand the impact of RPL23 depletion .

How does Recombinant 60S Ribosomal Protein L23 (rpl-23) contribute to chemoresistance in cancer, and what are the targeting strategies?

RPL23 appears to play a significant role in chemoresistance, particularly in epithelial ovarian cancer (EOC) cells resistant to cisplatin. Research findings demonstrate:

• Mechanisms of RPL23-mediated chemoresistance:

  • RPL23 is consistently upregulated in cisplatin-resistant cancer cell lines

  • It appears to promote epithelial-mesenchymal transition (EMT), a process associated with therapy resistance

  • Western blot analysis shows altered expression of EMT markers (E-cadherin, N-cadherin, Vimentin) in RPL23-overexpressing cells

  • RPL23 may enhance cellular survival pathways that counteract chemotherapy-induced apoptosis

• Targeting strategies and methodology:

  • siRNA-mediated knockdown of RPL23 has successfully restored cisplatin sensitivity in resistant cells

  • Combination therapy approaches using RPL23 inhibitors with conventional chemotherapy show promise

  • Researchers should measure IC50 values before and after RPL23 manipulation to quantify changes in drug sensitivity

  • Cell viability assays (MTT, CCK-8) at 24, 48, and 72 hours post-treatment are recommended for assessing resensitization effects

• Implementation guidance:

  • For in vitro models, use paired sensitive/resistant cell lines to compare RPL23 expression

  • Consider developing patient-derived xenografts from resistant tumors to test RPL23 targeting in vivo

  • Monitor not only cell death but also cellular senescence and autophagy as potential outcomes of RPL23 inhibition

When investigating RPL23's role in chemoresistance, researchers should employ both genetic (siRNA, shRNA) and pharmacological approaches, with careful attention to dose-response relationships and potential off-target effects .

What is the relationship between Recombinant 60S Ribosomal Protein L23 (rpl-23) and cancer metastasis?

Recent research has identified RPL23 as a driver of cancer metastasis, particularly in hepatocellular carcinoma (HCC). The relationship between RPL23 and metastasis is characterized by:

• Clinical correlations:

  • Higher RPL23 expression is observed in extrahepatic metastatic HCC (EHMH) compared to metastasis-free HCC (MFH)

  • RPL23 expression positively correlates with tumor vascular invasion (p=0.0070)

  • RPL23 levels associate with lung metastasis (p=0.0469) and advanced TNM stage (p=0.0346)

• Cellular mechanisms of metastasis promotion:

  • RPL23 enhances HCC cell migration and invasion in vitro

  • It affects actin filament formation, which is critical for cell motility

  • RPL23 facilitates metastasis by enhancing MMP9 mRNA stability

  • Phalloidin staining reveals that RPL23 silencing leads to disruption of actin filaments

• Experimental approaches to study RPL23-mediated metastasis:

  • Wound-healing assays for migration assessment

  • Transwell assays for invasion capacity

  • In vivo metastasis models using tail vein injection

  • RNA stability assays (actinomycin D chase) to measure MMP9 mRNA half-life

For comprehensive metastasis research, investigators should employ both in vitro and in vivo models, with particular attention to epithelial-mesenchymal transition markers and extracellular matrix remodeling enzymes when studying RPL23's role in the metastatic cascade .

What are the contradictions or knowledge gaps in current RPL23 research that require further investigation?

Despite significant advances, several critical knowledge gaps and contradictions exist in RPL23 research:

• Dual role in ribosome biology vs. extra-ribosomal functions:

  • While RPL23 is integral to ribosome structure, its non-canonical functions are increasingly recognized

  • Research paradigms need to distinguish between effects due to altered global translation versus specific regulatory roles

  • Researchers should design experiments that can differentiate these mechanisms, potentially using mutant RPL23 constructs that maintain structural but not regulatory functions

• Tissue-specific effects:

  • RPL23 appears to have different effects across cancer types

  • Some studies suggest tissue-specific interaction partners

  • Comparative proteomics of RPL23 complexes across different tissues would help resolve these discrepancies

• Therapeutic targeting challenges:

  • Targeting a ribosomal protein presents selectivity challenges

  • Current research lacks clarity on whether partial inhibition is sufficient for therapeutic benefit

  • Development of graded knockdown models would help establish therapeutic windows

• Upstream regulation:

  • The mechanisms controlling RPL23 expression are poorly understood

  • Transcriptional, post-transcriptional, and post-translational regulation require further study

  • Analysis of RPL23 promoter activity and miRNA regulation would fill important knowledge gaps

Researchers addressing these contradictions should employ systems biology approaches, including unbiased interactome studies, transcriptomic analyses following RPL23 manipulation, and detailed structure-function analyses to determine critical domains for specific functions .

What are the optimal conditions for expressing and purifying Recombinant 60S Ribosomal Protein L23 (rpl-23)?

For researchers working with recombinant RPL23, optimization of expression and purification is critical. Based on current methodologies:

• Expression systems comparison:

• Purification methodology:

  • Utilize histidine-tag or GST-tag fusion constructs for affinity purification

  • For His-tagged RPL23: Use Ni-NTA columns with imidazole gradient elution (50-300 mM)

  • Include protease inhibitors throughout purification process

  • Consider size exclusion chromatography as a second purification step

  • Validate protein identity by western blot and mass spectrometry

  • Assess purity by SDS-PAGE (aim for >95%)

• Optimization considerations:

  • For E. coli expression, induce at OD600 0.6-0.8 with 0.5-1.0 mM IPTG

  • Optimize induction temperature (16-37°C) and duration (3-24 hours)

  • Test multiple lysis buffers to maximize soluble protein recovery

  • For difficult expressions, consider fusion partners (SUMO, MBP) to enhance solubility

When validating purified RPL23, researchers should confirm not only purity but also biological activity through functional assays such as RNA binding assays or cell-based functional reconstitution experiments.

What experimental designs are recommended for investigating the RNA-binding properties of Recombinant 60S Ribosomal Protein L23 (rpl-23)?

To investigate the RNA-binding properties of RPL23, researchers should consider these methodological approaches:

• RNA Immunoprecipitation (RIP):

  • Cross-link protein-RNA complexes in vivo using formaldehyde or UV

  • Immunoprecipitate RPL23 using specific antibodies

  • Extract bound RNAs and identify by RT-PCR or sequencing

  • Include IgG control immunoprecipitations to assess background

  • Validate findings with recombinant protein binding assays

• Electrophoretic Mobility Shift Assay (EMSA):

  • Generate purified recombinant RPL23 protein

  • Prepare labeled RNA probes (radioactive or fluorescent)

  • Incubate protein with RNA under varying conditions

  • Analyze binding by native gel electrophoresis

  • Include competition assays with unlabeled RNA to confirm specificity

• CLIP-seq (Cross-linking immunoprecipitation):

  • UV cross-linking of RPL23-RNA complexes in living cells

  • Immunoprecipitation with RPL23-specific antibodies

  • High-throughput sequencing of bound RNAs

  • Bioinformatic analysis to identify binding motifs and targets

  • Validation of key targets with reporter assays

• RNA stability assays:

  • Treat cells with actinomycin D to inhibit transcription

  • Harvest RNA at time intervals (0, 2, 4, 8, 12 hours)

  • Measure target mRNA levels by qPCR relative to time zero

  • Compare half-lives in RPL23-overexpressing vs. control cells

  • Focus on cancer-relevant mRNAs (e.g., MMP9)

How can researchers effectively study the interaction between Recombinant 60S Ribosomal Protein L23 (rpl-23) and the Miz-1/c-Myc regulatory circuit?

To investigate the complex interaction between RPL23 and the Miz-1/c-Myc regulatory circuit, researchers should consider these methodological approaches:

• Co-immunoprecipitation (Co-IP) studies:

  • Perform reciprocal Co-IPs (RPL23, Miz-1, c-Myc)

  • Use both endogenous proteins and tagged versions

  • Include RNase treatment to determine if interactions are RNA-dependent

  • Analyze by western blot with specific antibodies

  • Consider proximity ligation assays for in situ visualization

• Chromatin Immunoprecipitation (ChIP):

  • Perform ChIP for Miz-1 and c-Myc at p15^Ink4b and p21^Cip1 promoters

  • Compare binding patterns in RPL23-depleted vs. control cells

  • Use sequential ChIP (re-ChIP) to identify co-occupied regions

  • Follow with qPCR or sequencing to quantify binding

• Reporter gene assays:

  • Construct luciferase reporters with p15^Ink4b and p21^Cip1 promoters

  • Co-transfect with expression vectors for RPL23, Miz-1, and c-Myc

  • Measure promoter activity under various combinations

  • Include mutant binding site controls

  • Analyze data using two-way ANOVA to detect interaction effects

• Dynamic protein expression analysis:

  • Create time-course experiments after RPL23 manipulation

  • Monitor expression changes in Miz-1, c-Myc, p15^Ink4b, and p21^Cip1

  • Use western blot, qPCR, and immunofluorescence

  • Establish temporal relationships between expression changes

  • Apply mathematical modeling to infer regulatory relationships

How can Recombinant 60S Ribosomal Protein L23 (rpl-23) expression be used as a prognostic biomarker in cancer?

RPL23 has demonstrated significant potential as a prognostic biomarker in various cancer types. Researchers interested in developing RPL23 as a clinical biomarker should consider:

• Tissue-based biomarker validation methodology:

  • Perform immunohistochemistry (IHC) on tissue microarrays with large patient cohorts

  • Develop standardized scoring systems (H-score or Allred score)

  • Correlate expression with clinicopathological features and survival outcomes

  • Calculate hazard ratios through multivariate Cox regression analysis

  • Determine optimal cut-off values using ROC curve analysis

• Circulating biomarker potential:

  • Investigate RPL23 protein levels in patient serum/plasma

  • Explore circulating tumor cells (CTCs) for RPL23 expression

  • Develop sensitive ELISA or other immunoassays for detection

  • Compare with established biomarkers for the specific cancer type

  • Conduct longitudinal studies to assess temporal changes

• Combined biomarker strategies:

  • Integrate RPL23 with other markers (e.g., c-Myc, Miz-1)

  • Develop weighted scoring algorithms

  • Validate in independent patient cohorts

  • Calculate net reclassification improvement (NRI) and integrated discrimination improvement (IDI)

Current evidence indicates that RPL23 expression correlates with several prognostic factors in HCC, including tumor vascular invasion (p=0.0070), lung metastasis (p=0.0469), and TNM stage (p=0.0346). These associations suggest that RPL23 may serve as a valuable component of prognostic models, particularly for predicting metastatic potential and treatment resistance. Researchers should conduct prospective studies to fully establish RPL23's clinical utility as a biomarker .

What are the most promising therapeutic approaches targeting Recombinant 60S Ribosomal Protein L23 (rpl-23) in cancer treatment?

Based on current research, several promising therapeutic approaches targeting RPL23 are emerging:

• RNA interference therapeutics:

  • siRNA/shRNA delivery systems (lipid nanoparticles, aptamer conjugates)

  • Target-specific design to minimize off-target effects

  • Combination with conventional chemotherapy (particularly cisplatin)

  • Pre-clinical testing workflow: in vitro validation → xenograft models → patient-derived xenografts

• Small molecule inhibitors:

  • High-throughput screening for compounds disrupting RPL23-RNA interactions

  • Structure-based drug design targeting specific RPL23 functional domains

  • Medicinal chemistry optimization for pharmacokinetic properties

  • Testing in chemoresistant cancer models

• Peptide-based approaches:

  • Design of peptides that mimic binding interfaces of RPL23 interacting partners

  • Cell-penetrating peptide conjugation for intracellular delivery

  • Stability enhancement through cyclization or non-natural amino acids

  • Evaluation in combination therapy settings

• Immunotherapeutic strategies:

  • Assessment of RPL23 as a tumor-associated antigen

  • Development of RPL23-targeted antibodies or chimeric antigen receptor T cells

  • Exploration of synthetic lethality with immune checkpoint inhibitors

  • Monitoring immune response to RPL23 in patients

Current evidence suggests that targeting RPL23 may be particularly effective in reversing chemoresistance and preventing metastasis. Research indicates that RPL23 knockdown restores sensitivity to cisplatin in epithelial ovarian cancer cells and inhibits metastatic processes in hepatocellular carcinoma. When developing therapeutic strategies, researchers should carefully evaluate potential systemic effects given RPL23's role in normal cellular function .

What technical challenges should researchers anticipate when investigating Recombinant 60S Ribosomal Protein L23 (rpl-23) in disease models?

Researchers working with RPL23 in disease models should anticipate several technical challenges:

• Essential gene considerations:

  • RPL23 is essential for ribosome function and complete knockout may be lethal

  • Use conditional or inducible systems (Tet-On/Off, Cre-loxP)

  • Carefully titrate knockdown levels to avoid confounding global translation effects

  • Include rescue experiments with exogenous RPL23 to confirm specificity

• Model system selection:

  • Different model systems show varying RPL23 dependency

  • Cell line panel testing is recommended before selecting models

  • Consider patient-derived xenografts for higher clinical relevance

  • For in vivo studies, assess tissue-specific expression patterns

• Technical artifacts in protein detection:

  • Antibody specificity issues may arise with ribosomal proteins

  • Validate antibodies with knockdown controls and recombinant proteins

  • Consider epitope tagging strategies for specific detection

  • Include appropriate loading controls for western blots

• Distinguishing direct from indirect effects:

  • RPL23 manipulation may affect global protein synthesis

  • Use polysome profiling to assess translational impacts

  • Include translatome analysis (e.g., ribosome profiling)

  • Design appropriate control experiments (other ribosomal proteins)

• Data interpretation complexities:

  • RPL23 has both canonical (ribosomal) and non-canonical functions

  • Effects may be context-dependent across tissue types and disease states

  • Multi-omics approaches may be needed to fully characterize mechanisms

  • Consider compensatory mechanisms that may emerge during long-term studies

By anticipating these challenges, researchers can design more robust experiments with appropriate controls and validation strategies. This is particularly important when investigating RPL23 as a therapeutic target, where specificity and mechanism of action must be clearly established .

What are the emerging research directions for Recombinant 60S Ribosomal Protein L23 (rpl-23) beyond cancer?

While cancer research has dominated the RPL23 field, several promising directions are emerging:

• Neurodegenerative disorders:

  • Investigation of RPL23's role in protein quality control mechanisms

  • Potential connections to proteostasis in neurodegenerative conditions

  • Exploration of RPL23-mediated stress responses in neuronal models

  • Development of specialized neuronal expression systems for RPL23 studies

• Immune system regulation:

  • Analysis of RPL23 in immune cell function and differentiation

  • Potential involvement in autoimmune disorders

  • Exploration of extra-ribosomal functions in immune signaling

  • Investigation of RPL23's role in inflammation resolution

• Developmental biology:

  • Examination of RPL23 expression during embryogenesis

  • Tissue-specific conditional knockout models to assess developmental roles

  • Relationship to stem cell maintenance and differentiation

  • Potential connections to congenital disorders

• Aging and longevity:

  • Investigation of RPL23's role in cellular senescence

  • Connections to mTOR signaling and longevity pathways

  • Assessment of RPL23 expression changes during aging

  • Interventional studies targeting RPL23 in age-related conditions

Researchers exploring these emerging areas should develop specialized model systems appropriate for the specific biological context, while leveraging the methodological approaches established in cancer research. Cross-disciplinary collaboration will be essential to fully elucidate RPL23's diverse roles across biological systems and disease states.

How can multi-omics approaches advance our understanding of Recombinant 60S Ribosomal Protein L23 (rpl-23) function?

Multi-omics approaches offer powerful strategies to comprehensively understand RPL23 function:

• Integrative omics methodology:

  • Combine transcriptomics, proteomics, and interactomics after RPL23 manipulation

  • Perform RNA-seq, ribosome profiling, and mass spectrometry on the same samples

  • Apply network analysis to identify key regulatory hubs

  • Use computational approaches to integrate datasets (WGCNA, DIABLO, etc.)

• Spatial transcriptomics and proteomics:

  • Apply emerging spatial technologies to map RPL23's subcellular localization

  • Investigate tissue-specific expression patterns in disease models

  • Correlate localization with function in different cellular compartments

  • Develop RPL23-specific nanobodies for live-cell imaging

• Single-cell approaches:

  • Perform single-cell RNA-seq with RPL23 manipulation

  • Investigate cell-to-cell variability in RPL23 expression

  • Identify distinct cellular subpopulations with differential RPL23 dependency

  • Apply trajectory analysis to understand temporal dynamics

• Structural biology integration:

  • Combine cryo-EM, X-ray crystallography, and NMR studies

  • Determine RPL23 binding interfaces with RNA and protein partners

  • Use structural insights to guide rational drug design

  • Apply molecular dynamics simulations to understand conformational changes